Literature DB >> 23980907

Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited.

Francesca Menconi1, Maria Antonietta Profilo, Marenza Leo, Eleonora Sisti, Maria Antonietta Altea, Roberto Rocchi, Francesco Latrofa, Marco Nardi, Paolo Vitti, Claudio Marcocci, Michele Marinò.   

Abstract

BACKGROUND: According to Rundle's curve, Graves' ophthalmopathy (GO) worsens during an initial phase up to a peak of maximum severity, then improves and reaches a static plateau, with the activity curve preceding the severity curve by a few months. To our knowledge, no studies have tried to replicate Rundle's curve, and very few have investigated the natural history of GO. Here, we studied GO natural history retrospectively and tried to identify factors that may affect it.
METHODS: A total of 65 patients with untreated GO underwent an eye assessment after a median of seven months after the appearance of GO and then after a median of 40 months. The primary endpoints were the variation of the single GO features and of the NOSPECS score, as well as the overall outcome of GO. The secondary endpoint was the influence of several variables (age, sex, smoking, GO and thyroid disease duration, thyroid treatment, thyroid status, thyroid volume, anti-TSH receptor autoantibodies) on the outcome of GO.
RESULTS: The majority of patients had mild, minimally active GO, and only five had a Clinical Activity Score (CAS) >3. There was a significant reduction of CAS (p<0.0001) and NOSPECS (p=0.01) between the first and last observation, with a timing pattern resembling Rundle's curve. This difference was confirmed even when patients with a CAS >3 at first observation were excluded. At the last observation, 50.8% of patients had improved, 33.8% had remained stable, and 15.4% had worsened moderately or substantially. The overall outcome of GO was not affected by any of the variables under examination.
CONCLUSIONS: In confirmation of Rundle's observations, untreated GO improves spontaneously with time in the majority of patients, with an activity peak between 13 and 24 months, which may have implications in determining the proper timing of GO treatments.

Entities:  

Mesh:

Year:  2013        PMID: 23980907      PMCID: PMC3887427          DOI: 10.1089/thy.2013.0240

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  29 in total

Review 1.  Natural history of thyroid eye disease.

Authors:  P Perros; P Kendall-Taylor
Journal:  Thyroid       Date:  1998-05       Impact factor: 6.568

2.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Prevalence, natural history and surgical treatment of exophthalmos.

Authors:  D H Streeten; G H Anderson; G F Reed; P Woo
Journal:  Clin Endocrinol (Oxf)       Date:  1987-07       Impact factor: 3.478

4.  Natural history of thyroid associated ophthalmopathy.

Authors:  P Perros; A L Crombie; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1995-01       Impact factor: 3.478

Review 5.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 6.  Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.

Authors:  A Eckstein; J Esser; K Mann; M Schott
Journal:  Pediatr Endocrinol Rev       Date:  2010-03

7.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

8.  Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?

Authors:  L Tallstedt; G Lundell; H Blomgren; J Bring
Journal:  Eur J Endocrinol       Date:  1994-05       Impact factor: 6.664

9.  A treatment strategy for Graves' orbitopathy.

Authors:  Claudio Marcocci; Aldo Pinchera; Michele Marinò
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-05

Review 10.  Immunosuppressive treatment of Graves' ophthalmopathy.

Authors:  W M Wiersinga
Journal:  Thyroid       Date:  1992       Impact factor: 6.568

View more
  22 in total

1.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

Review 2.  Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Giuseppe Giuffrida; Giacomo Sturniolo; Giovanni Squadrito; Alfredo Campennì; Silvia Morelli; Efisio Puxeddu; Eleonora Sisti; Francesco Trimarchi; Francesco Vermiglio; Michele Marinò
Journal:  Endocrine       Date:  2016-03-22       Impact factor: 3.633

Review 3.  Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?

Authors:  P Anagnostis; K Boboridis; F Adamidou; M Kita
Journal:  J Endocrinol Invest       Date:  2016-09-23       Impact factor: 4.256

4.  Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

Authors:  Marius N Stan; James A Garrity; Barbara G Carranza Leon; Thapa Prabin; Elizabeth A Bradley; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2014-10-24       Impact factor: 5.958

Review 5.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

6.  Natural history of graves' orbitopathy after treatment.

Authors:  Francesca Menconi; Marenza Leo; Elena Sabini; Teresa Mautone; Marco Nardi; Aldo Sainato; Stefano Sellari-Franceschini; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Endocrine       Date:  2016-10-05       Impact factor: 3.633

7.  Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO).

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-12-18       Impact factor: 4.256

8.  Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves' orbitopathy (GO): a new frontier for GO treatment?

Authors:  G Rotondo Dottore; I Ionni; F Menconi; G Casini; S Sellari-Franceschini; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2017-06-27       Impact factor: 4.256

9.  Count Ivan VIII Drašković: a case of Graves' orbitopathy?

Authors:  Maja Baretić; Velimir Altabas; Jelena Juri Mandić; Martina Matovinović; Gloria Lekšić
Journal:  Hormones (Athens)       Date:  2020-04-16       Impact factor: 2.885

10.  Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Authors:  Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.